OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR's predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: We included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated. RESULTS: Quantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96-5.45, P < 0.001), 1.27 (0.51-3.19, P = 0.61), 2.93 (1.68-5.11, P < 0.001), 2.82 (0.73-11.9, P = 0.13), and 4.13 (1.96-8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001). CONCLUSIONS: In patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.
OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR's predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: We included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated. RESULTS: Quantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96-5.45, P < 0.001), 1.27 (0.51-3.19, P = 0.61), 2.93 (1.68-5.11, P < 0.001), 2.82 (0.73-11.9, P = 0.13), and 4.13 (1.96-8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001). CONCLUSIONS: In patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.
Authors: Ria M Holstein; Santeri Seppälä; Johanna Kaartinen; Mari Hongisto; Harri Hyppölä; Maaret Castrén Journal: J Clin Med Date: 2022-06-08 Impact factor: 4.964
Authors: Esben Iversen; Morten Baltzer Houlind; Thomas Kallemose; Line Jee Hartmann Rasmussen; Mads Hornum; Bo Feldt-Rasmussen; Salim S Hayek; Ove Andersen; Jesper Eugen-Olsen Journal: Front Cell Dev Biol Date: 2020-06-12
Authors: Theis Bjerre-Christensen; Signe A Winther; Nete Tofte; Simone Theilade; Tarunveer S Ahluwalia; Maria Lajer; Tine W Hansen; Peter Rossing; Christian Stevns Hansen Journal: BMJ Open Diabetes Res Care Date: 2021-10
Authors: Sarah J Schrauben; Haochang Shou; Xiaoming Zhang; Amanda Hyre Anderson; Joseph V Bonventre; Jing Chen; Steven Coca; Susan L Furth; Jason H Greenberg; Orlando M Gutierrez; Joachim H Ix; James P Lash; Chirag R Parikh; Casey M Rebholz; Venkata Sabbisetti; Mark J Sarnak; Michael G Shlipak; Sushrut S Waikar; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Jeffrey R Schelling Journal: J Am Soc Nephrol Date: 2020-10-29 Impact factor: 14.978
Authors: Conxita Jacobs-Cachá; Ander Vergara; Clara García-Carro; Irene Agraz; Nestor Toapanta-Gaibor; Gema Ariceta; Francesc Moreso; Daniel Serón; Joan López-Hellín; Maria José Soler Journal: Clin Kidney J Date: 2020-08-11